San Diego-based mostly Viking Therapeutics marked by itself as a serious competitor in the weight loss drug current market in February immediately after revealing promising knowledge from a mid-stage demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when specified as a weekly injection As well as i